| Related Articles |
Cancers (Basel). 2020 Feb 12;12(2):
Authors: Wang L, Lui VWY
Abstract
Anaplastic lymphoma kinase (ALK) is mostly known for its oncogenic role in several human cancers. Recent evidences clearly indicate new roles of ALK and its genetic aberrations (e.g. gene rearrangements and mutations) in immune evasion, innate and cell-mediated immunity. New ALK-related immunotherapy approaches are demonstrating both preclinical and clinical promises. Here, we provide a timely review on the most updated laboratory and patient-related findings on ALK and immunity, which would grant us important insights for the development of novel ALK immunotherapies for ALK-altered cancers.
PMID: 32059449 [PubMed]
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου